| 15.82 -0.105 (-0.66%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 18.89 |
1-year : | 19.37 |
| Resists | First : | 16.17 |
Second : | 16.59 |
| Pivot price | 15.87 |
|||
| Supports | First : | 15.5 | Second : | 12.9 |
| MAs | MA(5) : | 15.92 |
MA(20) : | 15.93 |
| MA(100) : | 14.67  |
MA(250) : | 10.77 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 57.2 |
D(3) : | 58.6 |
| RSI | RSI(14): 45.2 |
|||
| 52-week | High : | 18.88 | Low : | 4.95 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ PSNL ] has closed above bottom band by 33.3%. Bollinger Bands are 90% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 37 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 15.93 - 16.01 | 16.01 - 16.09 |
| Low: | 15.43 - 15.54 | 15.54 - 15.63 |
| Close: | 15.65 - 15.82 | 15.82 - 15.96 |
Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.
Fri, 30 Oct 2026
Tempus may pay up to 50% cash as Personalis (PSNL) asks stockholders to approve their proposed merger. - Stock Titan
Fri, 30 Oct 2026
Personalis, Inc. (PSNL) Seasonal returns chart - Yahoo Finance Australia
Fri, 30 Oct 2026
Personalis, Inc. (PSNL) Seasonal returns chart - Yahoo Finance UK
Fri, 30 Oct 2026
PSNL Investigation Reminder: Personalis’ $16.25 per Share - GlobeNewswire
Tue, 27 Oct 2026
Personalis (Nasdaq:PSNL) - Stock Analysis - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 107 (M) |
| Shares Float | 86 (M) |
| Held by Insiders | 25.6 (%) |
| Held by Institutions | 65.5 (%) |
| Shares Short | 8,430 (K) |
| Shares Short P.Month | 8,380 (K) |
| EPS | -1.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.21 |
| Profit Margin | -153.9 % |
| Operating Margin | -150.3 % |
| Return on Assets (ttm) | -25.1 % |
| Return on Equity (ttm) | -50.4 % |
| Qtrly Rev. Growth | 30 % |
| Gross Profit (p.s.) | 0.08 |
| Sales Per Share | 0.65 |
| EBITDA (p.s.) | -0.98 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -92 (M) |
| Levered Free Cash Flow | -56 (M) |
| PE Ratio | -14.52 |
| PEG Ratio | 0 |
| Price to Book value | 7.15 |
| Price to Sales | 24.25 |
| Price to Cash Flow | -18.31 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|